Pfizer halts production at a legacy Hospira plant; China works to offer Indian drugmakers streamlined access; Roivant's Sinovant debuts with 11 assets.
Less than one day after Novartis’ CEO talked up a potential key approval for slow-growing Kisqali, the company has that approval in hand.
Patent litigation and long-dated payer contracts are among the “unacceptable” tactics Gottlieb criticized for stalling biosim competition.
The FDA is eyeing foreign imports to combat “dramatic price hikes” on old, competition-free drugs.
Johnson & Johnson has won FDA approval for Symtuza, a new once-a-day HIV drug, but faces a crowded market that includes Gilead's hot-selling Biktarvy.
Roche touted another win Thursday for Tecentriq. But the way some analysts see things, it may actually be a win for Merck's Keytruda
Roche’s Tecentriq is on a much-needed hot streak. On Tuesday, the immuno-oncology drug picked up an FDA breakthrough designation in liver cancer.
Baxter has been nailed with a warning letter for a plant in India that it got in its $625 million buyout of Claris Injectables.
With Brexit looming, AstraZeneca has taken up three lines of defense to forestall potential supply disruptions.
Even before Pfizer faced Trump's wrath for July price hikes, Novartis decided increasing its own prices wouldn’t be prudent, its CEO said Wednesday.
